V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005507 | 10003443 | 1.65 | 75.6 | Curative (C) | 2017-06-26 | 2017-06-26 | Folfirinox | N | null | 10519609 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN |
| 10005508 | 10003444 | 1.83 | 92 | Disease modification (D) | 2015-07-07 | 2015-08-01 | CRIZOTINIB | 02 | N | 10519876 | CAPECITABINE + MITOMYCIN + RT |
| 10005509 | 10003445 | 1.6 | 73.6 | Adjuvant (A) | 2018-08-16 | 2018-08-19 | MYELOMA XI TRIAL | 2 | N | 10520074 | CETUXIMAB |
| 10005510 | 10003445 | 1.6 | 51 | Palliative (P) | 2017-12-22 | 2018-01-07 | Ipilimumab | null | N | 10520074 | BRENTUXIMAB |
| 10005511 | 10003446 | 1.51 | 75.3 | Curative (C) | 2018-02-07 | 2018-02-09 | Bevacizumab+Carbo+Pacliaxel | N | N | 10520743 | MPV |
| 10005512 | 10003447 | 1.6 | 58.15 | Palliative (P) | 2016-07-27 | 2016-07-27 | Sorafenib | 2 | N | 10521024 | DOXORUBICIN |
| 10005513 | 10003448 | null | null | Adjuvant (A) | 2019-01-12 | 2019-01-17 | ANAGRELIDE | N | N | 10521114 | MPV |
| 10005514 | 10003448 | 1.71 | 90.4 | Disease modification (D) | 2015-03-20 | 2015-04-04 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | N | N | 10521114 | DOXORUBICIN EMBOLISATION |
| 10005515 | 10003448 | 1.56 | 94.8 | Disease modification (D) | 2018-07-09 | 2018-07-30 | VEPEMB | 02 | N | 10521114 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10005516 | 10003449 | null | 91.2 | Adjuvant (A) | 2014-12-17 | 2015-01-09 | BALLAD Trial | null | N | 10522394 | CISPLATIN + FLUOROURACIL |
| 10005517 | 10003449 | null | null | Disease modification (D) | 2016-01-06 | 2016-01-08 | CHLORAMBUCIL + OBINUTUZUMAB | 1 | N | 10522394 | LOMUSTINE |
| 10005518 | 10003450 | 1.89 | 77.3 | Curative (C) | 2016-02-02 | 2016-02-02 | Cladribine + Rituximab | null | null | 10522500 | LENALIDOMIDE |
| 10005519 | 10003451 | 1.69 | null | Palliative (P) | 2018-04-27 | 2018-04-27 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10523571 | CISPLATIN + FLUOROURACIL |
| 10005520 | 10003452 | null | 67.2 | Curative (C) | 2017-04-16 | 2017-08-01 | CHLVPP | 2 | N | 10523986 | DA |
| 10005521 | 10003453 | 1.68 | 62.1 | Curative (C) | 2019-05-13 | 2019-05-13 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 10524119 | DABRAFENIB + TRAMETINIB |
| 10005522 | 10003453 | 1.71 | 55 | Palliative (P) | 2018-12-10 | 2018-12-10 | Ipilimumab | N | N | 10524119 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005523 | 10003454 | 1.6 | 63.5 | Neo-adjuvant (N) | 2016-11-13 | 2016-12-01 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | N | N | 10526979 | TEMOZOLOMIDE |
| 10005524 | 10006881 | 1.79 | 96.8 | Curative (C) | 2018-12-20 | 2018-12-23 | BORTEZOMIB + THALIDOMIDE | 02 | N | 10526993 | DOXORUBICIN + OLARATUMAB |
| 10005525 | 10006881 | null | 55.6 | Palliative (P) | 2016-06-19 | 2016-06-19 | CHLVPP | N | null | 10526993 | FEC + DOCETAXEL + TRASTUZUMAB |
| 10005526 | 10003455 | 1.71 | 58.6 | Curative (C) | 2013-10-28 | 2013-11-05 | Sunitinib | N | N | 10529619 | VEMURAFENIB |
| 10005527 | 10003455 | 1.77 | 81.7 | Palliative (P) | 2019-04-02 | 2019-04-09 | LENALIDOMIDE | 2 | N | 10529619 | AML16 TRIAL |
| 10005528 | 10003456 | 1.81 | 69.9 | null | 2017-07-30 | 2017-08-05 | DA 3 + 10 | 2 | N | 10529970 | MITOMYCIN INTRAVESICULAR |
| 10005529 | 10003457 | 1.9 | 97.7 | Adjuvant (A) | 2018-09-03 | 2018-09-16 | MYELOMA XI TRIAL | N | N | 10530818 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10005530 | 10003458 | 1.74 | 70.9 | Curative (C) | 2015-10-16 | 2015-10-16 | Cisplatin +Fluorouracil (2 wk) | 01 | N | 10531776 | MITOMYCIN INTRAVESICULAR |
| 10005531 | 10003459 | 1.63 | 105.1 | Palliative (P) | 2019-04-21 | 2019-05-25 | BLEOMYCIN | 2 | N | 10531831 | SORAFENIB |
| 10005532 | 10003460 | 1.57 | 71 | null | 2016-10-09 | 2016-10-09 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 02 | N | 10533075 | CARBO + FLUOROURACIL |
| 10005533 | 10003461 | 1.67 | 103.8 | Neo-adjuvant (N) | 2017-12-03 | 2017-12-25 | Bortezomib + MELPHALAN | N | null | 10534017 | IPILIMUMAB + NIVOLUMAB |
| 10005534 | 10003462 | 1.77 | 100 | Neo-adjuvant (N) | 2020-02-11 | 2020-02-16 | Cisplatin + Etoposide + RT | 02 | N | 10534288 | TEMOZOLOMIDE |
| 10005535 | 10003463 | 1.67 | 53.6 | null | null | 2016-03-29 | BORTEZOMIB + THALIDOMIDE | 02 | N | 10535385 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10005536 | 10003463 | 1.55 | 70.4 | Adjuvant (A) | 2018-12-10 | 2018-12-14 | Carboplatin + Docetaxel | N | N | 10535385 | CARBOPLATIN + DOCETAXEL |
| 10005537 | 10003464 | 1.76 | 85.9 | Disease modification (D) | null | 2018-12-18 | CAP + RT | 02 | N | 10537600 | BORTEZOMIB + THALIDOMIDE |
| 10005538 | 10003465 | null | null | Palliative (P) | 2014-07-23 | 2014-08-08 | Folfirinox | 02 | null | 10539530 | AFATINIB |
| 10005539 | 10003465 | 1.61 | 0 | Adjuvant (A) | 2017-03-28 | 2017-04-24 | AFATINIB | 02 | N | 10539530 | NOT MATCHED |
| 10005540 | 10003465 | 1.72 | 116 | Curative (C) | 2018-03-24 | 2018-03-29 | Capecitabine (21days) + Carboplatin | Y | N | 10539530 | BEVACIZUMAB |
| 10005541 | 10003466 | null | 92 | Palliative (P) | 2018-01-12 | 2018-02-07 | Raltitrexed | 02 | N | 10540527 | IBRUTINIB |
| 10005542 | 10003467 | 1.72 | 63 | Curative (C) | 2017-10-18 | 2017-10-20 | Melphalan IV High dose | 02 | null | 10540818 | PERM TRIAL |
| 10005543 | 10003467 | 1.68 | null | Palliative (P) | 2019-02-08 | 2019-02-19 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10540818 | DACARBAZINE |
| 10005544 | 10003467 | 1.71 | 92.1 | Disease modification (D) | 2015-09-15 | 2015-09-18 | Sunitinib | 02 | N | 10540818 | CETUXIMAB + OXALIPLATIN + MDG |
| 10005545 | 10003468 | 1.63 | 83.9 | Palliative (P) | 2017-10-24 | 2017-12-16 | CARBOPLATIN + RT | N | N | 10541889 | EP |
| 10005546 | 10003469 | 1.54 | 80.5 | Palliative (P) | 2018-01-31 | 2018-01-31 | Ipilimumab | Y | N | 10542103 | LOMUSTINE + PROCARBAZINE + VINCRISTINE |
| 10005547 | 10003470 | 1.51 | 55.3 | Palliative (P) | 2018-07-04 | 2018-07-19 | Temozolomide 150mg/m2 | N | N | 10542224 | LIPOSOMAL DOXORUBICIN |
| 10005548 | 10006886 | 1.63 | null | Palliative (P) | 2014-06-12 | 2014-06-12 | Trastuzumab 21 day loading dose | 2 | N | 10542759 | TRASTUZUMAB |
| 10005549 | 10003471 | 1.57 | 102 | null | 2018-04-15 | 2018-04-18 | IBRUTINIB | N | N | 10543270 | MPV |
| 10005550 | 10003471 | null | 77.3 | Palliative (P) | 2019-03-19 | 2019-03-20 | Cisplatin +Fluorouracil (3 wk) | N | N | 10543270 | CLADRIBINE |
| 10005551 | 10003471 | 1.75 | 108 | Palliative (P) | 2016-09-18 | 2016-09-20 | CISPLATIN + FLUOROURACIL | 02 | N | 10543270 | CETUXIMAB + RT |
| 10005552 | 10003472 | 1.61 | null | Disease modification (D) | 2019-02-12 | 2019-02-12 | OCTREOTIDE | Y | N | 10545056 | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10005553 | 10003473 | 1.73 | null | Palliative (P) | 2016-12-04 | 2016-12-12 | Bevacizumab 5mg/kg | N | N | 10545258 | PAZOPANIB |
| 10005554 | 10003473 | 1.78 | 94 | Curative (C) | 2016-12-11 | 2017-01-08 | CETUXIMAB + RT | N | N | 10545258 | CETUXIMAB |
| 10005555 | 10003474 | 1.79 | 89.5 | null | 2019-03-15 | 2019-03-22 | PATHOS Trial | N | N | 10545657 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005556 | 10003474 | 1.7 | 87 | null | 2018-03-13 | 2018-03-28 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10545657 | DACARBAZINE |